TURNOVER (x1000 NOK)
NET PROFIT (x1000 NOK)
EMPLOYEES
10x Genomics Sweden AB
Closing information (x1000 NOK)
| Closing information | 2023/12 | 2022/12 | 2021/12 |
| Turnover |
271,033
|
242,422
|
155,234 |
| Financial expenses |
316
|
8
|
12 |
| Earnings before taxes |
155,837
|
128,483
|
73,519 |
| EBITDA |
165,516
|
137,499
|
76,248 |
| Total assets |
375,057
|
246,318
|
132,277 |
| Current assets |
355,768
|
219,627
|
105,822 |
| Current liabilities |
35,706
|
53,166
|
38,203 |
| Equity capital |
339,350
|
193,153
|
94,074 |
| - share capital |
51
|
47
|
49 |
| Employees (average) |
39
|
45
|
38 |
Financial ratios
| Fiscal year | 2023/12 | 2022/12 | 2021/12 |
| Solvency |
90.5%
|
78.4%
|
71.1% |
| Turnover per employee |
6,950
|
5,387
|
4,085 |
| Profit as a percentage of turnover |
57.5%
|
53.0%
|
47.4% |
| Return on assets (ROA) |
41.6%
|
52.2%
|
55.6% |
| Current ratio |
996.4%
|
413.1%
|
277.0% |
| Return on equity (ROE) |
45.9%
|
66.5%
|
78.2% |
| Change turnover |
11,409
|
91,854
|
79,549 |
| Change turnover % |
4%
|
61%
|
105% |
| Chg. No. of employees |
-6
|
7
|
18 |
| Chg. No. of employees % |
-13%
|
18%
|
90% |
Total value of public sale
| Fiscal year | 2023/12 | 2022/12 | 2021/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.